NCT07706179 Alisertib Metastatic breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Move from a broad disease map to a decision-ready trial dossier. This focused report examines NCT07706179—Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer—using PatSnap Clinical Trials, Drug & Asset, and Company & Deal Intelligence MCP evidence. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why NCT07706179 is a hot trial to watch

Metastatic breast cancer is increasingly segmented by mechanism, biomarker, line of therapy, geography and endpoint architecture. NCT07706179 is notable because it tests Alisertib in a Phase 2 design while Clinical benefit defined as partial tumor response (PR) serves as the main decision variable. The value of this program will depend on whether the protocol converts biological rationale into a clinically interpretable and operationally credible readout.

PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add mechanism, development-status and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The design should be read as an evidence architecture, not just a phase label. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment. Enrollment of 10 participants across United States shapes statistical precision, execution risk and external validity. A strong readout will need to be interpreted against baseline risk, prior treatment, assessment schedule, missing-data handling and the clinical relevance of the observed effect.

• Primary: Clinical benefit defined as partial tumor response (PR) — 12 weeks
• Primary: Clinical benefit defined as complete tumor response (CR) — 12 weeks
• Primary: Clinical benefit defined as decline in circulating tumor DNA (ctDNA) — 12 weeks
• Secondary: Evaluate safety of adding alisertib to usual care by assessing adverse events — 12 weeks
• Secondary: BRD8 signature expression — 12 weeks

Benchmark readouts in the surrounding field

• Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study (Phase 3): AE(led to discontinuation) = 5.0 % ; AE(led to discontinuation) = 13.0 %
• A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects With Stage IV NSCLC Whose Tumors Harbor a KRAS G12C Mutation in Need of First-line Treatment (CodeBreaK 201) (Phase 2): Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) = 26.8 percentage of participants (95% Confidence Interval, 14.2 - 42.9)
• A Global, Randomised, Phase 3, Open-label Study of REGN2810 (ANTI-PD 1 Antibody) Versus Platinum Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic PD L1+Non-small Cell Lung Cancer (Phase 3): OS(Median) = 13.7 months (95% Confidence Interval, 11.2 - 16.2); OS(Median): Hazard Ratio (HR) = 0.661(95% CI, 0.553 - 0.790), P-Value = <0.0001

These indexed results are contextual benchmarks rather than direct head-to-head evidence. Cross-trial comparisons can be distorted by population, treatment line, endpoint definition, follow-up and analysis set. Their value is to clarify what magnitude and type of evidence the market already recognizes.

Build a living trial monitor: connect to PatSnap MCP Servers and track protocol changes, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: Alisertib (Phase 2; Aurora A)

Company & Deal Intelligence context: University of Wisconsin-Madison — https://www.wisc.edu

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes that connect activity with function, symptoms, survival or treatment burden.
• Sequencing evidence: comparative data after the most relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment status, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. The most important inflection point is not always the headline data release; a change in endpoint, population or ownership can alter probability of success months earlier.

Bottom line

NCT07706179 is a focused lens on Metastatic breast cancer development. Its value will be determined by whether Alisertib can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from existing benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.